Population pharmacokinetics of tenofovir in AIDS patients

Journal of Clinical Pharmacology

Volumn 48, Issue 11, 2008, Pages 1282-1288

  Gagnieu, Marie Claude ^a   El Barkil, Mirna ^c   Livrozet, Jean Michel ^a   Cotte, Laurent ^d   Miailhes, Patrick ^d   Boibieux, André ^e   Guitton, Jérôme ^b,c   Tod, Michel ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c UNIVERSITÉ LYON 1   (France)

^d HÔTEL DIEU   (France)

^e CROIX ROUSSE HOSPITAL   (France)

Author keywords

Drug interaction; Intraindividual variability; Pharmacokinetics; Tenofovir

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; COVARIANCE; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; VARIANCE;

EID: 54049156182     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008322908     Document Type: Article

References (21)

1. Barditch-Crovo P., Deeks SG, Collier A., et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother. 2001 ; 45: 2733-2739.
2. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004 ; 43: 595-612.
3. Ray AS, Cihlar T., Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006 ; 50: 3297-3304.
4. Kearney BP, Yale K., Shah J., Zhong X., Flaherty JF Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet. 2006 ; 45: 1115-1124.
5. Jullien V., Treluyer JM, Rey E., et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother. 2005 ; 49: 3361-3366.
6. Kearney BP, Mathias A., Mittan A., Sayre J., Ebrahimi R., Cheng AK Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006 ; 43: 278-283.
7. Tong L., Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother. 2007 ; 51: 3498-3504.
8. Kiser J., Carten M., Aquilante C., et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIVinfected patients. Mol Ther. 2008 ; 83: 265-272.
9. Brundage RC, Yong FH, Fenton T., Spector SA, Starr SE, Fletcher CV Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother. 2004 ; 48: 979-984.
10. El Barkil M., Gagnieu M-C., Guitton J. Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 ; 854 (1-2). 192-197.
11. Premaud A., Le Meur Y., Debord J., et al. Maximum a posteriori Bayesian estimation of MPA pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005 ; 27: 354-361.
12. Karlsson MO, Sheiner LB The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993 ; 21: 735-750.
13. Beal SL, Ludden T., Boeckmann A. NONMEM Users Guide, Version VI. Ellicott City, MD: GloboMax, ICON Development Solutions ; 2006.
14. White DB, Walawander CA, Liu DY, Grasela TH Evaluation of hypothesis testing for comparing two populations using NONMEM analysis. J Pharmacokinet Biopharm. 1992 ; 20: 295-313.
15. Parke J., Holford NH, Charles BG A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Meth Programs Biomed. 1999 ; 59: 19-29.
16. Mentré F., Escolano S. Prediction discrepancies for the evaluation of non-linear mixed-effects models. J Pharmacokin Pharmacodyn. 2006 ; 33: 345-367.
17. Brendel K., Comets E., Laffont C., Laveille C., Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006 ; 23: 2036-2049.
18. Revell P., O'Doherty MJ, Tang A., Savidge GF Folic acid absorption in patients infected with the human immunodeficiency virus. J Intern Med. 1991 ; 230: 227-231.
19. Zimmermann AE, Pizzoferrato T., Bedford J., Morris A., Hoffman R., Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006 ; 42: 283-290.
20. Lanzafame M., Lattuada E., Rapagna F., et al. Tenofovir-associated kidney disease and interactions between tenofovir and other antiretrovirals [letter]. Clin Infect Dis. 2006 ; 42: 1656-1657.
21. Winston JA, Shepp DH The role of drug interactions and monitoring in the prevention of tenofovir-associated kidney disease [letter]. Clin Infect Dis. 2006 ; 42: 1657-1658.